Ahmad Younes, MD
Interventional Cardiology · Fleming Island, FLNPI 1609147560
Payments from drug & device makers
Across 299 payments — averaging $75.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$7K
- Medtronic$4K
- Edwards Lifesciences$2K
- Abbott$2K
- Abiomed$906
- Inquis Medical, Inc.$646
- plus $5K from 32 others
What the payments were for
- Consulting fees$2501%
- Travel & lodging$7,84135%
- Food & beverage$14,38364%
- Education$260%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 33 | $7,470 |
| Medtronic(2 entities) | 65 | $4,482 |
| Edwards Lifesciences | 12 | $2,010 |
| Abbott | 26 | $1,939 |
| Abiomed | 19 | $906 |
| Inquis Medical, Inc. | 8 | $646 |
| Terumo Medical Corporation | 7 | $638 |
| Inari Medical, Inc. | 10 | $605 |
| Boston Scientific | 8 | $517 |
| Amgen | 10 | $470 |
| Endologix LLC | 3 | $434 |
| Bard Peripheral Vascular, Inc. | 11 | $369 |
| Johnson & Johnson | 19 | $342 |
| Actelion Pharmaceuticals US, Inc. | 8 | $247 |
| Penumbra, Inc. | 8 | $178 |
| Orthofix Medical, Inc. | 1 | $136 |
| Cardiovascular Systems Inc. | 3 | $132 |
| Kestra Medical Technology Services, Inc. | 3 | $100 |
| Integra Lifesciences Corporation | 1 | $98 |
| Pfizer | 6 | $87 |
| BD | 1 | $86 |
| AstraZeneca | 7 | $85 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $84 |
| Cvrx, Inc. | 3 | $83 |
| Amarin Pharma, Inc. | 4 | $75 |
| Chiesi USA, Inc. | 2 | $35 |
| Biosense Webster, Inc. | 2 | $35 |
| Lantheus Medical Imaging, Inc. | 2 | $35 |
| Alnylam Pharmaceuticals Inc. | 2 | $31 |
| Boehringer Ingelheim | 2 | $25 |
| Veryan Medical Incorporated | 1 | $23 |
| Cordis US CORP. | 1 | $18 |
| Philips North America LLC | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Lundbeck LLC | 1 | $14 |
| Thrombolex, Inc. | 1 | $12 |
| Acutus Medical, Inc. | 1 | $12 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AngioVac$4,603
- AlphaVac$1,935
- CoreValve Evolut$1,730
- Omnilink Elite vascular stent system$862
- IN.PACT Admiral$455
- Resolute$432
- Auryon Laser System 100-120 Vac$421
- Torus Stent Graft System$408
- ENDOCROSS Device$408
- Impella$383
- FLOWTRIEVER CATHETER, S$353
- CT THROMBECTOMY SYSTEM KIT$353
- HawkOne$332
- Aventus$314
- EVENITY$276
- R2P MISAGO$188
- TRICLIP$171
- EVOQUE$165
- WATCHMAN Access System$159
- Optis Coronary Imaging System$157
How this compares
$22,500 in reported general payments places this provider in the 65th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 47 | $57,171 |
| EliquisApixaban | 55 | $52,181 |
| Rosuvastatin Calcium | 137 | $2,847 |
| ClopidogrelClopidogrel Bisulfate | 173 | $2,648 |
| Cilostazol | 128 | $2,514 |
| Ezetimibe | 12 | $1,146 |
| Metoprolol Succinate | 86 | $890 |
| Enoxaparin Sodium | 12 | $880 |
| Atorvastatin Calcium | 49 | $796 |
| Nifedipine ErNifedipine | 22 | $724 |
| Losartan Potassium | 35 | $511 |
| FenofibrateFenofibrate Nanocrystallized | 15 | $433 |
| Amlodipine Besylate | 43 | $432 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 24 | $261 |
| Carvedilol | 22 | $222 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $342 | $57,17147 claims |
| PfizerEliquis | $87 | $52,18155 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in Fleming Island
- Dominick AngiolilloJacksonville$4M
- Douglas SpriggsClearwater$3.2M
- Rakesh PrashadOcala$3.1M
- Aldo Martinez FleitesMiami Lakes$2.2M
- Rohit AminPensacola$2M
- Roberto CubedduNaples$2M
- Arthur LeeGainesville$2M
- Ruby SatpathyJacksonville$1.8M
- Santhosh MathewsBradenton$1.7M
- Pedro Martinez-ClarkMiami$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.